Alice S. Bexon

The European Society for Medical Oncology (ESMO) is a leading medical oncology society that provides a professional network for its members and works with national societies across Europe. The non-profit company is based in Lugano, Switzerland. ESMO's position on a wide range of legislative and non-legislative policy files on both EU and levels is available to learn about. Raffaella Casolino is the third ESMO young medical oncologist serving as a cancer expert on the WHO Cancer Control team. ESMO's Young Oncologists Corner is dedicated to providing educational and networking opportunities for medical oncologists under 40.

The American Society of Clinical Oncology is a non-profit organization founded in 1964 with the overarching goals of improving cancer care and prevention. More than 27,000 oncology practitioners belong to ASCO, representing all oncology disciplines and subspecialties. Members include physicians and health-care professionals in all levels of the practice of oncology. American Society of Clinical Oncology is the world’s leading professional organization representing physicians who treat people with cancer. ASCO’s members set the standard for patient care worldwide and lead the way in carrying out clinical research aimed at improving the prevention, diagnosis, and treatment of cancer. ASCO's efforts are also directed toward advocating for policies that provide access to high-quality care for all patients with cancer and at supporting the increased funding for clinical and translational research.

Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ.

Sevion Therapeutics, Inc. operates as Biopharmaceutical Company. It discovers, develops and acquires product candidates for the treatment of cancer and immunological diseases. The company was founded on September 30, 1999 and is headquartered in San Diego, CA.

Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA.